elmiron
bene-arzneimittel gmbh - pentosano polisulfato natris - cistitas, intersticinis - urologiniai preparatai - elmiron yra skirtas gydyti šlapimo pūslės skausmo sindromas būdingas glomerulations arba hunner's pažeidimai suaugusiesiems, sergantiems vidutinio sunkumo ir sunkus skausmas, skubumą ir šlapinimosi dažnumas.
betnovate
glaxosmithkline trading services limited - betametazonas - odos emulsija - 1 mg/g - betamethasone
enosat
pharmaceutical works polpharma s.a. - fuzido rūgštis/betametazonas - kremas - 20 mg/1 mg/g - betamethasone and antibiotics
peditrace
fresenius kabi ab - cinko chloridas/vario chloridas dihidratas/mangano chloridas tetrahidratas/natrio selenitas/natrio fluoridas/kalio jodidas - koncentratas infuziniam tirpalui - 521 µg/53,7 µg/3,6 µg/4,38 µg/126 µg/1,31 µg/ml - i.v. solution additives
fervex
upsa sas - paracetamolis/feniramino maleatas/askorbo rūgštis - granulės geriamajam tirpalui paketėlyje - 500 mg/200 mg/25 mg; 280 mg/10 mg/100 mg; 500 mg/25 mg/200 mg - paracetamol, combinations excl. psycholeptics
buprenorphine g.l. pharma [bupensan]
g.l. pharma gmbh - buprenorfinas - poliežuvinės tabletės - 8 mg; 2 mg; 4 mg - buprenorphine
finasteride teva
teva pharma b.v. - finasteridas - plėvele dengtos tabletės - 5 mg - finasteride
ayvakyt
blueprint medicines (netherlands) b.v. - avapritinib - virškinimo trakto stromos navikai - kiti antinavikiniai vaistai agentai, baltymų kinazės inhibitoriai - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - krūties navikai - antinavikiniai vaistai - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
tempier
nvt, uab - paracetamolis/pseudoefedrino sulfatas/dekstrometorfano hidrobromidas - milteliai geriamajam tirpalui - 500 mg/30 mg/15 mg - other cold preparations